Latest research on Xarelto

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.

Latest findings

Rivaroxaban (BAY 59-7939, Xarelto®, Bayer HealthCare) is an oxazolidinone derivative with a molecular weight of 436 Da and high selectivity for direct inhibition of FXa (Table 2). [source, 2013]
For deep vein thrombosis prophylaxis, all the patients had either subcutaneous nadroparin (Fraxiparine, GlaxoSmithKline, UK) 40 mg daily or oral rivaroxaban (Xarelto, Bayer Schering Pharma, Germany) 10 mg daily and mechanotherapy with compression stockings from the second day after the surgery. [source, 2013]
Dabigatran etexilate (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) are new oral anticoagulants (NOACs) that are approved in North America for reducing the risk of venous thromboembolism after hip or knee replacement and for stroke prevention in non-valvular atrial fibrillation. [source, 2013]
Rivaroxaban (Xarelto, Bayer Australia), prevention of thromboembolism following hip or knee replacement. [source, 2013]
Rivaroxaban (Xarelto, Bayer), prevention of venous thrombosis in hip or knee replacement surgery. [source, 2013]
Single technology appraisal of rivaroxaban (Xarelto) for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. [source, 2013]
Currently, new generations of anticoagulants like Pradaxa and Xarelto are available as well. [source, 2012]
Rivaroxaban (Xarelto, Janssen Pharmaceuticals, Titusville, NJ) is an oral direct inhibitor of factor Xa with excellent bioavailability (80–100%), rapid onset of action (maximum inhibitory activity is reached within 1–4 hours), no significant dietary interactions [37]. [source, 2012]
Oral BAY 59-7939 is for the prevention of venous thromboembolism [322]. [source, 2011]
For thromboprophylaxis, orally administered Xarelto (10 mg) was administered once daily until discharge, starting 6–8 h postoperatively. [source, 2011]